Felix System commercialisation update
Filed with ASX · · 4 pages · English
Australian-based bio-separations and reproductive biotechnology company, Memphasys Limited (ASX: MEM), is pleased to provide an update in relation to commercialisation of the Company’s Felix System, which separates sperm from raw semen by a proprietary process combining electrophoresis and size exclusion membranes. The process selects high quality sperm whilst excluding cellular contaminants such
Story so far
Earlier from Memphasys
- Follow up sales of FelixTM System
- MEM Achieves ISO 13485 Compliance
- Appendix 4D and Half Year Report and Accounts
- First Felix System commercial sale for clinical IVF use
- First Sale of FelixTM in Research Application
Later from Memphasys
- Monash IVF clinical study enrols first patient using FELIX
- Suspension from Official Quotation
- $3.36 capital raising to accelerate FELIX commercialisation
- Rights Issue Closure and Shortfall Notification
- FELIX System commercialisation, regulatory plan and trial
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys